Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

• Status: Completed
• Trial end date: 2016-11-11
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Ono Pharmaceutical Co. Ltd
• Treatments: Nivolumab

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Subjects with previously treated advanced malignant solid tumor

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

• For certain subjects, willing and able to provide pre-treatment tumor sample

Exclusion Criteria:

• Known or suspected central nervous system metastases or central nervous system as the only source of disease

• Other concomitant malignancies (with some exceptions per protocol)

• Active, known or suspected autoimmune disease